Moderna extends gains

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...
Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...
As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural ...
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
Copyright 2025 The Associated Press. All Rights Reserved. A local resident receives the Moderna COVID-19 vaccine shot at a ...
Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.
Moderna’s stock tumbles after a disappointing outlook for revenue and the need to accelerate its cost-cutting plan.
No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...